Toronto, ON, Canada, October 2, 2012 -- Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Sandra Beach Lin to the Board of Directors. Ms. Beach Lin is an experienced C-suite executive with a wealth of polymer experience in multiple industries, including medical devices.
Ms. Beach Lin brings 30 years of polymer, technology and innovation experience to the IBI Board, having served in C-suite positions at Celanese Corporation and AveryDennison Corporation, and in senior executive roles at Honeywell International and Alcoa. She also brings private company experience to IBI, having recently retired as President & CEO of Calisolar Inc., a privately-held provider of solar silicon. Ms. Beach Lin has been a member of the Board of Directors of WESCO International, a $6B global industrial distributor, since 2002. She was recently appointed to the Board of Directors of $15B American Electric Power, one of the largest electric utilities in the United States.
“I have been impressed with Interface Biologics’ technology, their potential for applications across a broad range of clinical disciplines and their current partnerships”, commented Ms. Beach Lin. “I look forward to contributing my industry experience to grow IBI into a valuable provider of polymer technology & products to multiple industries.”
“We are extremely pleased to have Sandra join our Board of Directors”, stated Tom Reeves, President and CEO, Interface Biologics. “Her broad specialty chemicals company experience will be invaluable as we look to increase our market penetration in medical device applications as well as extend our reach to industrial applications. Furthermore, her public board experience will provide important guidance for Interface as we continue to progress down the commercialization continuum.”
ABOUT INTERFACE BIOLOGICS, INC.
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI’s primary technology focus areas are anti-thrombogenic additives and programmable combination drug delivery devices. IBI, a University of Toronto spinoff, is located at the MaRS Centre in Toronto, Canada. For more information about Interface Biologics, please visit www.interfacebiologics.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Julie Fotheringham - Partner, Hageman Communications